|Bid||1.1500 x 2041500|
|Ask||1.1700 x 261700|
|Day's range||1.1500 - 1.1850|
|52-week range||0.9700 - 1.7450|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
New U.S. Clinical studies provide further validation for Aroa Biosurgery's Myriad™ as products also approved for use in India.
Aroa Biosurgery’s proprietary Endoform® platform shown to attract stem cells, with further validation from peer-reviewed publication in PLOS ONE.
Aroa Biosurgery Limited commences trading on the ASX today following the completion of an initial public offering that raised $45m from investors.